

CROATIA

Croatian Health Insurance Fund
Margaretska 3, Zagreb
info@hzzo.hr

Agency for Medicinal Products and Medical Devices
Ksaverska cesta 4, Zagreb
halmed@halmed.hr

Pop: 3 850 894 inhb.
GDP pc: 18 731 €
VAT on MP: 5%
CHE pc: 930,62 €

Pharmaceutical pricing and reimbursement policies

Agency for Medicinal Products and Medical Devices



PRICING

The maximum permitted wholesale price of a medicinal product
/international referencing through annual calculation/



The exceptional increase in the maximum permitted wholesale price of a medicinal product



consent

- VAT for all medicines = 5 %
- Wholesale margins = differentiated wholesale margin

The wholesale price of the medicine in EUR	Wholesale margin up to %
< 49,99	8,5
50,00 – 299,99	7,5
300,00 – 599,99	6,5
600,00 – 1.199,99	6,0
1.200,00 – 5.999,99	5,5
6.000,00 – 25.999,99	5,0
26.000,00– 66.000,00	4,5

Dispensed via **pharmacies** and **spec. stores**

POM

Pharmacy retail price (PRP)
=
wholesaler price+ pharmacy margin + VAT

OTC

- Out of pocket payments

REIMBURSEMENT

Croatian Health Insurance Fund (CHIF)



Reimbursement lists for both, **out-patient (POM)** and **in-patient sector**:

A list - basic reimbursement list of medicines

B list- supplementary reimb. list including insured person's co-payment for medicines

New medicine up to 100 % max price (HALMED)
Required cut down prices for generic medicines:
1st generic medicine – up to 30%
2nd generic medicine – up to 5%
3rd generic medicine – up to 5% etc.

New medicine up to 100 % max price (HALMED)
Required cut down prices for biosimilars:
1st biosimilar – up to 20%
2nd biosimilar – up to 5%
3rd biosimilar – up to 5% etc.

Out-patient sector

MP (POM) on **A-list** = up to 100% covered by CHIF
MP (POM) on **B-list** = part of the amount covered by CHIF + part is patient's co-payment

Payment by CHIF to pharmacies includes service charged for dispensing (pharmacy fee 1,28 € dispensing by prescription)

Internal price referencing

Medicines included on the reimbursement lists
- cluster formed at 3rd to 5th level of ATC for out patient medicine
- at 5th level of ATC for in-patient medicines

In-patient sector

Cost of medicines included in the reimbursement

- Specially intended means and payments*

Particularly expensive medicines:

- medicine for rare diseases, orphans
- extremely high price of therapy (↑therapy cost annual level exceeds per patient an amount greater than 3xGDP p.c. for the previous calendar year)

- Public procurement

* Pricing and managed entry agreements (expensive medicines separately paid to hospitals for treatment for in-patients)